A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 67, Issue 2, Pages 334-343
Publisher
Wiley
Online
2014-11-11
DOI
10.1002/art.38949
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Janus kinase inhibitors in autoimmune diseases
- (2013) John J O'Shea et al. ANNALS OF THE RHEUMATIC DISEASES
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis
- (2012) Y Tanaka et al. ANNALS OF THE RHEUMATIC DISEASES
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Developing an effective treatment algorithm for rheumatoid arthritis
- (2012) E. C. Keystone et al. RHEUMATOLOGY
- Kinase inhibitors: a new class of antirheumatic drugs
- (2012) Vasileios Kyttaris Drug Design Development and Therapy
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- (2011) David T. Felson et al. ARTHRITIS AND RHEUMATISM
- Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs
- (2011) Roy Fleischmann et al. ARTHRITIS AND RHEUMATISM
- Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
- (2010) J. L. Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- Rheumatoid arthritis
- (2010) David L Scott et al. LANCET
- The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo
- (2009) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Janus kinases in immune cell signaling
- (2009) Kamran Ghoreschi et al. IMMUNOLOGICAL REVIEWS
- Selectivity and therapeutic inhibition of kinases: to be or not to be?
- (2009) Kamran Ghoreschi et al. NATURE IMMUNOLOGY
- Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate
- (2008) G Wells et al. ANNALS OF THE RHEUMATIC DISEASES
- Therapeutic targeting of Janus kinases
- (2008) Marko Pesu et al. IMMUNOLOGICAL REVIEWS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started